# Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

> **NCT03276910** · PHASE1 · UNKNOWN · sponsor: **Association Athletes For Transparency** · enrollment: 24 (estimated)

## Conditions studied

- Sports Drug Abuse

## Interventions

- **DRUG:** EPREX
- **DRUG:** sodium chloride AGUETTANT 0.9%

## Key facts

- **NCT ID:** NCT03276910
- **Lead sponsor:** Association Athletes For Transparency
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-08
- **Primary completion:** 2017-12-22
- **Final completion:** 2018-06-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2017-09-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276910, "Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03276910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*